Neurology and Neurosurgery

46-60 of 114

• 

  RestartResume

  First-Line Management of HR+/HER2-Low Breast Cancer With Brain Metastases

  MinuteCE®

  First-Line Management of HR+/HER2-Low Breast Cancer With Brain Metastases

  • 

    

    Barbara O'Brien, MD

  • 

    

    Nadia Harbeck, MD, PhD

  1.00 program credits

• 

  RestartResume

  Brain Metastases Management: From Detection to Multidisciplinary Care

  MinuteCE®

  Brain Metastases Management: From Detection to Multidisciplinary Care

  • 

    

    Barbara O'Brien, MD

  1.00 program credits

• 

  RestartResume

  Sequencing Systemic and Local Therapy in HER2-Overexpressing Metastatic NSCLC 

  MinuteCE®

  Sequencing Systemic and Local Therapy in HER2-Overexpressing Metastatic NSCLC 

  • 

    

    Benjamin Levy, MD

  • 

    

    Melin Khandekar, MD, PhD

  1.00 program credits

• 

  RestartResume

  EGFR-Mutated NSCLC With Brain Metastases: Navigating ADC Treatment Decisions

  MinuteCE®

  EGFR-Mutated NSCLC With Brain Metastases: Navigating ADC Treatment Decisions

  • 

    

    Benjamin Levy, MD

  • 

    

    Melin Khandekar, MD, PhD

  1.00 program credits

• 

  RestartResume

  Rethinking Secondary Stroke Prevention: The Emerging Role of Factor XI Inhibition

  CME/CE

  Rethinking Secondary Stroke Prevention: The Emerging Role of Factor XI Inhibition

  • 

    

    Mukul Sharma, MD, MSc, FRCPC

  • 

    

    Ashkan Shoamanesh, MD, MSc, FRCPC

  0.75 credits

• 

  RestartResume

  Minimal By Design: Define MSE Endpoints

  MinuteCE®

  Minimal By Design: Define MSE Endpoints

  • 

    

    Christyn Edmundson, MD

  • 

    

    Gil I. Wolfe MD, FAAN

  1.00 program credits
• advertisement

• 

  RestartResume

  Turning Flares Into Function: Flag Uncontrolled Disease

  MinuteCE®

  Turning Flares Into Function: Flag Uncontrolled Disease

  • 

    

    Christyn Edmundson, MD

  • 

    

    Gil I. Wolfe MD, FAAN

  1.00 program credits

• 

  MinuteCE®

  Treat. Target. Transform: Applying Treat-to-Target Principles in the Management of Generalized Myasthenia Gravis (gMG)

  • 

    

    Christyn Edmundson, MD

  • 

    

    Gil I. Wolfe MD, FAAN

  1.00 credits 10 episodes

• 

  RestartResume

  Scorecards That Matter: Use MG-ADL, MG-MMT, QMG, QoL

  MinuteCE®

  Scorecards That Matter: Use MG-ADL, MG-MMT, QMG, QoL

  • 

    

    Christyn Edmundson, MD

  1.00 program credits

• 

  RestartResume

  Escalate With Intention: Stepwise, Target-Anchored Moves

  MinuteCE®

  Escalate With Intention: Stepwise, Target-Anchored Moves

  • 

    

    Christyn Edmundson, MD

  • 

    

    Gil I. Wolfe MD, FAAN

  1.00 program credits

• 

  RestartResume

  When to Begin FcRn: Initiation Criteria, Key Evidence

  MinuteCE®

  When to Begin FcRn: Initiation Criteria, Key Evidence

  • 

    

    Christyn Edmundson, MD

  • 

    

    Gil I. Wolfe MD, FAAN

  1.00 program credits

• 

  RestartResume

  The IgG Clock: Redose Using IgG Kinetics

  MinuteCE®

  The IgG Clock: Redose Using IgG Kinetics

  • 

    

    Christyn Edmundson, MD

  • 

    

    Gil I. Wolfe MD, FAAN

  1.00 program credits
• advertisement

• 

  RestartResume

  Early Clues, Lasting Impact: Detecting and Treating Alzheimer’s Disease in Its Earliest Stages

  CME/CE

  Early Clues, Lasting Impact: Detecting and Treating Alzheimer’s Disease in Its Earliest Stages

  • 

    

    Anton P. Porsteinsson, MD

  • 

    

    Vijay K. Ramanan, MD, PhD

  1.00 credits

• 

  RestartResume

  New Pathways in the Treatment of DMD

  CME/CE

  New Pathways in the Treatment of DMD

  • 

    

    Erika Finanger, MD, MS

  • 

    

    Aravindhan Veerapandiyan, MD

  1.00 credits

• 

  RestartResume

  Optimizing the Role for Corticosteroids Within the Evolving DMD Treatment Landscape

  CME/CE

  Optimizing the Role for Corticosteroids Within the Evolving DMD Treatment Landscape

  • 

    

    Stephen Chrzanowski, MD, PhD

  • 

    

    Aravindhan Veerapandiyan, MD

  1.00 credits

• Prev
• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• Next